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Objective. To investigate whether assessment of C-reactive protein (CRP) and apolipoproteins, besides the traditional lipid profile,
enhances the assessment process for the risk of acute coronary syndrome (ACS). Methods. The study group consisted of 220
consecutive patients admitted to hospital within the first 6 hours from the onset of chest pain. Patients were diagnosed with
unstable angina (n = 96), non-ST-elevation myocardial infarction (NSTEMI; n = 57), or ST-elevation myocardial infarction
(STEMI; n = 67). ACS patients were compared with 116 healthy volunteers in a case-control study. The serum was assayed on
admission for CRP, apolipoproteins ApoAI and ApoB100, and lipid parameters. Results. The highest concentrations of CRP were
found in NSTEMI and STEMI, with a median value four-fold higher in ACS patients than in controls (P < 0.0001). Only CRP
significantly increased the probability of ACS development (adjusted odds ratio for a 1 mg/L increase 1.90; 95% confidence interval
[CI] 1.34–2.89) and explained 90% of the variation for ACS development. Similarly, we demonstrated the highest diagnostic
accuracy for CRP among all investigated markers (area under the curve 0.80; 95% CI 0.75–0.85). Conclusions. Our study indicates
that CRP superiorly to apolipoproteins and lipid profile facilitates the risk stratification for ACS occurrence.
1. Introduction
Despite great progress in pharmacotherapy and interven-
tional treatment, acute coronary syndromes (ACS) remain
the major cause of mortality and morbidity in the modern
world [1]. Inflammation plays a key role in the initiation
and promotion of atherosclerotic lesions and can trigger
ACS by the induction of plaque instability. C-reactive (CRP)
protein is an extensively studied inflammatory factor whose
prognostic value in cardiovascular diseases in recent years has
become increasingly important [2–7]. Additionally, CRP is
no longer merely considered a marker but also emerges as a
mediator of atherosclerosis [8, 9].
Thus, considering the generally available lipid profile a
tool for risk assessment, it seems that CRP and the lipid
profile besides the patient’s clinical characteristics could lead
to the most tangible benefit for assessing the risk of ACS
development. On the other hand, in recent years the value
of CRP in this setting has been extensively debated. In
a large meta-analysis of 22 prospective studies in healthy
individuals, Danesh et al. found that in studies published
after 2000, the prognostic value of CRP in predicting ACS
was much weaker than in a meta-analysis of research results
from before 2000 [10]. This led to a critical review of the
role of CRP in the assessment of occurrence of cardiovascular
events and less optimistic application of its determination for
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the primary and secondary prevention [10, 11]. In contrast
with these data, a recent individual participant meta-analysis
of 160,309 patients confirmed substantial continuous asso-
ciations between CRP concentration and the risks of ACS,
ischaemic stroke, and vascular mortality [2].
One of the best known risk factors and a primary target of
therapy is elevated concentration of low-density lipoprotein
cholesterol (LDL-C). Despite many studies indicating the
need for determination of LDL-C in patients at risk of ACS,
it is more and more often suggested that focusing solely
on LDL-C is not an optimal diagnostic and therapeutic
strategy [12]. This attitude is driven by several important
limitations associated with LDL-C. Triglyceride-rich lipopro-
teins, including very low-density lipoproteins (VLDL) and
intermediate-density lipoproteins (IDL), also exert athero-
genic properties. Patients, who achieved a reduction in LDL-
C even below 70 mg/dL, still are at the so-called residual risk
of atherothrombotic events [13]. Atherogenic factors that
influence this residual risk consist of elevated IDL and VLDL
levels and the presence of small dense LDL particles, which
are not detected in a basic lipid panel.
The coexistence of high triglycerides (TG) and low high-
density lipoprotein cholesterol (HDL-C), called atherogenic
dyslipidemia, is associated with elevated apolipoprotein B
concentration. While the role of apolipoproteins in coronary
risk assessment is an evolving debate, the apoB : apoA-I ratio
is becoming increasingly important [14, 15]. The results
of the AMORIS and INTERHEART studies demonstrated
that the apoB : apoA-I ratio was the strongest predictor for
myocardial infarction among all investigated variables and
most importantly, like CRP, was able to identify subjects at
high risk even when LDL-C values were considered normal
[16, 17].
As the routine determination of apolipoproteins and
CRP in ACS risk stratification remains controversial, this
study aims to investigate whether evaluation of these markers
enhances, besides the traditional lipid profile, the assessment
process for the risk of ACS development.
2. Material and Methods
2.1. Study Design and Conduction. The study was designed
as a case-control study. We screened consecutive patients
admitted due to the initial diagnosis of ACS to the Depart-
ment of Cardiology and Internal Medicine at The University
Hospital in Bydgoszcz within the first 6 hours from the
onset of chest pain. The exclusion criteria were as follows:
(i) chronic heart failure (New York Heart Association class
II–IV), (ii) acute heart failure (Killip class II–IV), (iii)
pulmonary embolism within 6 months preceding the enrol-
ment, (iv) creatinine concentration >176.8 mmol/l, (v) ACS
within 6 weeks preceding the enrolment, (vi) the presence
of features suggestive of an active inflammatory process on
admission, and (vii) therapy with steroids, immunosuppres-
sive agents, and nonsteroidal anti-inflammatory drugs
(excluding low doses of aspirin).
Among 267 subjects, who fulfilled the requirements of
the study according to the inclusion and exclusion criteria,
47 patients were diagnosed with unspecified chest pain
or other heart diseases and were excluded from further
analysis. The final study group consisted of 220 patients
(91 females and 129 males, aged 64 ± 12 years). All these
patients met clinical criteria of ACS. Electrocardiographic
examination was performed on admission and thereafter
if clinically indicated. Echocardiography, stress tests, and
cardiac catheterization were performed if needed. Patients
with ACS were subsequently definitely diagnosed with
unstable angina (UA; n = 96), non-ST-elevation myocardial
infarction (NSTEMI; n = 57), or ST-elevation myocardial
infarction (STEMI; n = 67). Clinically healthy volunteers (61
women and 55 men, aged 52 ± 9 years) with no evidence
of present renal, metabolic or inflammatory disease, heart
failure, and recent myocardial infarction served as controls.
Dyslipidemia was defined by at least one abnormal
level of serum lipid parameters: total cholesterol (TC)
>5.2 mmol/L, TG> 1.7 mmol/L, LDL-C> 2.6 mmol/L, HDL-
C < 1.3 mmol/L for women and <1.0 mmol/L for men
according to the modified definition of Third Report of the
National Cholesterol Education Program [18]. Hypertension
was diagnosed if systolic blood pressure exceeded 140 mmHg
and/or diastolic blood pressure was above 90 mmHg. Base-
line characteristics of study participants are presented in
Table 1.
The study protocol was approved by the Bioethics Com-
mittee at Nicolaus Copernicus University in Torun Col-
legium Medicum in Bydgoszcz and written informed consent
was obtained from all patients and controls.
2.2. Blood Sampling and Laboratory Analyses. Venous blood
samples were collected from patients on hospital admission
within 6 hours of chest pain onset. Fasting venous blood
samples from controls were collected in the morning. Serum
was assayed on admission for cardiac troponin I (cTnI) and
lipid parameters (ARCHITECT ci8200, Abbott Diagnostics).
Any increase of cTnI above 0.032 ng/mL (the 99th percentile
for the healthy population measured with a 10% coefficient
of variation) was considered a positive result.
High-sensitivity CRP (hsCRP) was measured using the
BN II System nephelometer (N High-Sensitivity CRP; Siem-
ens Healthcare Diagnostics, Deerfield, IL, USA), providing
excellent precision with the coefficient of variation reported
by the manufacturer of less than 10%. Coefficients of varia-
tion for hsCRP estimated in our laboratory were below 3.5%
and below 4.5% for hsCRP concentrations below 1 mg/L and
above 3 mg/L, respectively. The lower limit of CRP detection
was 0.17 mg/L. Serum apoA-I and apoB100 concentrations
were measured in samples stored frozen at −80◦C no longer
than 6 months (ARCHITECT ci8200) and the ratio of
apoB : apoA-I was calculated. ApoB concentration >0.9 g/L
was classified as abnormal. TC : HDL-C <4 and TG : HDL-
C <3 were regarded as optimal. According to Walldius and
Jungner [16] the apoB : apoA-I ratio over 0.8 for women and
0.9 for men was considered to represent high risk of ACS.
2.3. Statistical Analysis. We performed an internal pilot study
for estimating the final sample size. CRP concentrations for
the first 100 patients in the study group and for the first 50
patients in the control group were, respectively, 5.55 ± 7.19
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Table 1: Baseline characteristics of the study participants.
Parameter ACS patients (n = 220) Control group (n = 116) P
Age (years) 64 ± 12 52 ± 9 0.01
TC (mmol/L) 4.96 (4.11–5.99) 4.75 (4.26–5.09) 0.024
LDL-C (mmol/L) 3.18 (2.35–3.93) 2.79 (2.3–3.15) 0.002
HDL-C (mmol/L) 1.16 ± 0.31 1.45 ± 0.31 <0.0001
Non-HDL-C (mmol/L) 3.85 (3.1–4.65) 3.2 (2.79–3.54) <0.0001
TG (mmol/L) 1.3 (0.99–1.89) 0.92 (0.71–1.88) <0.0001
TC : HDL-C 4.43 (3.72–5.42) 3.23 (2.82–3.72) <0.0001
TG : HDL-C 2.77 (1.88–4.08) 1.47 (0.99–2.08) <0.0001
LDL-C : HDL-C 2.77 (2.16–3.55) 1.85 (1.56–2.27) <0.0001
apoA-I (g/L) 1.27 ± 0.24 1.41 ± 0.31 <0.0001
apoB (g/L) 0.81 (0.65–1.00) 0.72 (0.61–0.86) 0.0009
apoB : apoA-I 0.64 (0.52–0.8) 0.51 (0.45–0.62) <0.0001
hsCRP (mg/L) 2.79 (1.12–6.08) 0.69 (0.36–1.35) <0.0001
BMI (kg/m2) 26.8 (24.5–29.8) 24.4 (22.1–27.7) 0.014
Women 41% (91) 53% (61)
<0.05
Men 59% (129) 47% (55)
Dyslipidemia 87% (191) 57% (66) <0.00001
Hypertension 74% (163) 20% (23) <0.00001
Diabetes mellitus 26% (57) 0 <0.00001
Smoking 54% (119) 27% (31) 0.0001
Family history of premature CAD 35% (77) 26% (30) ns
Prior statin use 69% (152) 5% (6) <0.0001
ACS: acute coronary syndrome; apoA-I: apolipoprotein A-I; apoB: apolipoprotein B; apoB : apoA-I: apolipoprotein B to apolipoprotein A-I ratio; BMI: body
mass index; CAD: coronary artery disease; HDL-C: high-density lipoprotein cholesterol; hsCRP: high-sensitivity C-reactive protein; LDL-C: low-density
lipoprotein cholesterol; LDL-C : HDL-C: low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio; non-HDL-C: nonhigh-density
lipoprotein cholesterol; TC: total cholesterol; TC : HDL-C: total cholesterol to high-density lipoprotein cholesterol ratio; TG: triglycerides; TG : HDL-C:
triglycerides to high-density lipoprotein cholesterol ratio.
and 1.41 ± 1.61 mg/L. Based on these results and assuming
a 2-sided alpha value of 0.05, we calculated that enrolment
of 220 patients in the study group and 116 patients in the
control group would provide a 99.8 power to demonstrate
a significant difference in CRP concentrations between
patients with and without ACS. We decided to obtain such
high power to be able to conduct credible multivariate
analyses.
The Kolmogorov-Smirnov test was used to assess nor-
mality of distribution of investigated parameters. Data were
expressed as mean ± standard deviation and median with
25th–75th percentiles. Variances in the two groups with
normal distribution were examined using the Levene’s test.
Comparison between the groups was performed by using the
Chi-square test for categorical variables, the unpaired Stu-
dent’s t-test, ANOVA followed by the Tukey test for normally
distributed variables, and the Mann-Whitney U-test and the
Kruskal-Wallis test for nonnormally distributed variables,
with the post hoc Dunn’s tests. Pearson correlation was
used to analyze associations between variables. Variables with
nonparametric distribution underwent logarithmic trans-
formation. P value <0.05 was considered statistically sig-
nificant. Logistic regression was performed to determine
associations between baseline parameters and the risk of ACS
development. Clinical utility of laboratory parameters was
determined by analysis of Receiver Operating Characteristic
(ROC) curves. Statistical analysis and sample size calculation
were performed using SPSS 17.0 software package (SPSS,
Chicago, IL, USA) and Statistica 10.0 for Windows (StatSoft,
Tulsa, OK, USA).
3. Results
3.1. Characteristics of Participants and Major Findings of Basic
Statistics. Baseline characteristics of the study participants,
including lipid parameters, CRP, and apolipoproteins con-
centrations constituting major cardiovascular risk factors,
are shown in Table 1. All quantitative variables differed
significantly between both groups. Patients with ACS, com-
pared with controls, had higher concentrations of TC, LDL-
C, non-HDL-C, and TG, but lower levels of HDL-C and
apoA-I. They also presented significantly higher values of
atherogenic indexes such as TC : HDL-C, LDL-C : HDL-C,
apoB : apoA-I, and TG : HDL-C, reflecting insulin resistance,
as well as fourfold higher median concentration of C-
reactive protein in comparison with the control group. Both
groups were characterized by the presence of dyslipidemia,
hypertension, and smoking. A quarter of ACS patients were
diagnosed with type 2 diabetes.
In the course of further analysis the patients were divided
into groups based on the specific clinical diagnosis (Table 2).
UA patients formed the largest group, also characterized by
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Table 2: Characteristics of patients according to the type of ACS.
Parameter UA (n = 96) NSTEMI (n = 57) STEMI (n = 67) P value Post hoc∗
Age (years) 63 ± 10 64 ± 12 66 ± 14 ns —
TC (mmol/L) 4.83 (3.93–5.99) 5.27 (4.52–6.33) 4.8 (4.11–5.76) ns —
LDL-C (mmol/L) 2.84 (2.3–3.77) 3.69 (2.99–4.11) 3.18 (2.45–3.8) 0.007 UA versus STEMI
HDL-C (mmol/L) 1.13 ± 0.33 1.89 ± 0.31 1.16 ± 0.28 ns —
Non-HDL-C (mmol/L) 3.74 (2.97–4.55) 4.27 (3.62–5.17) 3.67 (2.89–4.39) 0.022 UA versus STEMI
TG (mmol/L) 1.37 (1.01–2.08) 1.2 (0.85–1.6) 1.28 (0.98–1.97) ns —
TC : HDL-C 4.28 (3.73–5.2) 4.52 (3.78–5.45) 4.43 (3.30–5.31) ns —
TG : HDL-C 2.89 (2.05–4.71) 2.32 (1.7–3.63) 3.03 (1.96–4.02) ns —
LDL-C : HDL-C 2.5 (1.98–3.25) 3.2 (2.5–4.03) 2.76 (1.93–3.36) 0.005 UA versus STEMI
apoA-I (g/L) 1.27 ± 0.27 1.29 ± 0.22 1.26 ± 0.23 ns —
apoB (g/L) 0.76 (0.59–0.95) 0.88 (0.79–1.1) 0.78 (0.64–0.92) 0.001
UA versus STEMI
STEMI versus NSTEMI
apoB : apoA-I 0.61 (0.47–0.77) 0.73 (0.6–0.89) 0.63 (0.48–0.76) 0.005
UA versus STEMI
STEMI versus NSTEMI
hsCRP (mg/L) 2.13 (0.96–4.63) 3.58 (1.49–6.86) 3.6 (1.4–9.07) 0.008
UA versus STEMI
UA versus NSTEMI
BMI (kg/m2) 26.7 (24.7–31.2) 26.2 (24.1–29.3) 27.4 (24.6–28.9) ns —
∗
Presence of a statistically significant difference in the post hoc analysis.
apoA-I: apolipoprotein A-I; apoB: apolipoprotein B; apoB : apoA-I: apolipoprotein B to apolipoprotein A-I ratio; BMI: body mass index; HDL-C: high-density
lipoprotein cholesterol; hsCRP: high-sensitivity C-reactive protein; LDL-C: low-density lipoprotein cholesterol; LDL-C : HDL-C: low-density lipoprotein
cholesterol to high-density lipoprotein cholesterol ratio; non-HDL-C: nonhigh-density lipoprotein cholesterol; ns: not significant; NSTEMI: non-ST elevation
myocardial infarction; STEMI: ST elevation myocardial infarction; TC: total cholesterol; TC : HDL-C: total cholesterol to high-density lipoprotein cholesterol
ratio; TG: triglycerides; TG : HDL-C: triglycerides to high-density lipoprotein cholesterol ratio; UA: unstable angina.
lower age compared with those with STEMI and NSTEMI.
Statistically significant differences between the UA and
STEMI groups were found for LDL-C, non-HDL-C and
the LDL-C : HDL-C, ratio. ApoB concentration and the
apoB : apoA-I ratio were substantially higher in STEMI
patients compared with the UA and NSTEMI groups, while
between the latter two no major differences were found. CRP
concentration was markedly higher in patients with STEMI
and NSTEMI compared with those with UA.
Correlation analysis showed no significant relationships
between serum CRP and other variables in the control group.
In contrast, in the ACS group, weak but statistically signifi-
cant correlations were observed between CRP concentration
and the apoB : apoA-I ratio (R = 0.16; P = 0.02), the
TG : HDL-C ratio (R = 0.15; P = 0.02), the LDL-C : HDL-
C ratio (R = 0.15; P = 0.02), and the TC : HDL-C ratio (R =
0.14; P = 0.03), respectively. Also a weak but statistically
significant negative correlation between CRP and HDL-C
(R = −0.14; P = 0.04) was found in this group.
3.2. The Probability of ACS Presented Using Logistic Regression.
The odds ratio for the occurrence of ACS among the
conventional risk factors was highest for hypertension, then
followed by age, dyslipidemia, and smoking (Table 3). The
probability of ACS occurrence, depending on the measured
laboratory parameters and calculated ratios, was presented
using logistic regression after adjustment for age, gender, and
smoking status successively. In order to avoid data redun-
dancy, the variables have been divided into primary variables
(Table 4) and secondary variables (data not presented).




OR 95% CI P
Age (for a 10-year increase) 5.49 3.36–8.97 <0.00001
Diabetes mellitus — — —
Dyslipidemia 4.98 2.92–8.53 <0.00001
Family history of premature CAD 1.38 0.76–2.52 ns
Hypertension 12.9 6.7–24.9 <0.00001
Sex (male versus female) 1.28 0.81–2.00 ns
Smoking 3.22 1.78–5.81 0.0001
ACS: acute coronary syndrome; CAD: coronary artery disease; CI: confi-
dence interval; ns: not significant; OR: odds ratio.
Measured analytes have been identified as the primary
variables, while variables resulting from calculations of other
parameters were classified as secondary. The estimator of risk
for ACS occurrence was the logistic odds ratio, which was
given along with a 95% confidence interval and significance
level.
The results of logistic regression for the primary variables
are presented in Table 4. The first model designed, Model 0
unadjusted, was highly significant and based on the result
of a pseudomeasure of quality of the fit-R2 Nagelkerke
explained 47% of the variation for ACS occurrence. In this
model, all TC, HDL-C, LDL-C, TG, apoA-I, and apoB did not
facilitate the risk stratification for ACS development. Only
CRP significantly increased the probability of the occurrence
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Table 4: The risk of the acute coronary syndrome for primary variables.
Parameter
Crude odds ratio Adjusted odds ratio
Model 0∗ OR (95% CI)
P value for the model
Model 1 OR (95% CI)
P value for the model
Model 2 OR (95% CI)
P value for the model
Model 3 OR (95% CI)
P value for the model
TC
1.08 (0.94–1.22) 1.10 (0.98–1.23) 1.12 (1.01–1.25) 1.04 (0.83–1.3)
ns ns 0.029 ns
LDL-C
0.94 (0.82–1.07) 0.92 (0.82–1.03) 0.9 (0.81–1.00) 0.99 (0.8–1.23)
ns ns 0.05 ns
HDL-C
0.89 (0.78–1.01) 0.9 (0.8–1.00) 0.88 (0.8–0.98) 0.84 (0.67–1.06)
ns ns 0.019 ns
TG
0.99 (0.96–1.02) 0.99 (0.97–1.02) 0.98 (0.96–1.01) 1.00 (0.96–1.05)
ns ns ns ns
apoA-I
0.99 (0.98–1.01) 0.96 (0.94–0.99) 0.97 (0.95–0.99) 0.99 (0.96–1.02)
ns 0.002 0.005 ns
apoB
1.01 (0.99–1.03) 1.01 (0.98–1.03) 1.01 (0.98–1.04) 1.01 (0.95–1.07)
ns ns ns ns
hsCRP
1.60 (1.32–1.94) 1.55 (1.21–1.98) 1.64 (1.26–2.12) 1.66 (1.2–2.29)
0.0001 0.0001 0.0001 0.002
∗
Model 0 unadjusted: χ2 = 131.7; df = 7; P < 0.001; log-likelihood = 275.5; R2 Cox and Snell = 0.34; R2 Nagelkerke = 0.47.
Model 1 adjusted for age: χ2 = 241.9; df = 8; P < 0.001; log-likelihood = 165.3; R2 Cox and Snell = 0.53; R2 Nagelkerke = 0.74.
Model 2 adjusted for age and sex: χ2 = 251.0; df = 9; P < 0.001; log-likelihood = 156.2; R2 Cox and Snell = 0.54; R2 Nagelkerke = 0.75.
Model 3 adjusted for age, sex, and smoking status: χ2 = 219.7; df = 10; P < 0.001; log-likelihood = 64.6; R2 Cox and Snell = 0.62; R2 Nagelkerke = 0.86.
apoA-I: apolipoprotein A-I; apoB: apolipoprotein B; CI: confidence interval; HDL-C: high-density lipoprotein cholesterol; hsCRP: high-sensitivity C-reactive
protein; LDL-C: low-density lipoprotein cholesterol; ns: not significant; OR: odds ratio; TC: total cholesterol; TG: triglycerides.
of ACS (by 60%). Model 1 after adjustment for age was
also highly significant and explained approximately 74% of
the variation for the presence of ACS. Among the primary
variables only CRP increased the risk of ACS (by approxi-
mately 55%). In contrast, apoA-I significantly reduced the
probability of ACS occurrence. Another model, which was
also highly significant and explained approximately 75%
of the variability for ACS development, was designed after
adjustment for age and sex. TC affected the risk of ACS in
12%, whereas HDL-C and apoA-I markedly lowered this risk.
In this model, CRP still remained the strongest predictor of
ACS occurrence. The last of the models, model 3 for the
primary variables, was adjusted for age, sex, and smoking
status. This model was also highly significant and explained
approximately 86% of the variation for the presence of ACS.
CRP increased the probability of ACS occurrence roughly by
66%.
Table 5 displays the results of logistic regression models
with both the primary and secondary variables. The analyzed
parameters were naturally correlated with one another. Size
distortions associated with the collinearity of independent
quantitative variables depended on the value of the cor-
relation coefficient between the two variables. A prelimi-
nary analysis of correlations between lipid variables from
Table 5 revealed only moderate strength of the correlation
coefficients between these variables. In addition, we run a
tolerance analysis that indicated that these variables can be
tolerated in the model.
Model 0, adjusted neither for age, sex, nor smoking,
was highly significant and based on the result of a pseudo
measure of quality of the fit-R2 Nagelkerke explained 49%
of the variation for the presence of ACS. In this model,
CRP was the only significant predictor for the occurrence of
ACS, increasing the probability of disease by 60%. Model 1,
after adjustment for age, was highly significant and explained
75% of variation for ACS development. In this model, CRP
was the only variable enhancing the probability of ACS.
While the predictive value of CRP alone in Model 1 was
56%, adjustment for age and sex, as performed in Model
2, increased it to 64%. The highest odds ratio for ACS
occurrence was obtained in Model 3 (including adjustment
for age, sex, and smoking status) for the primary and
secondary variables. This model was also highly significant
and explained 90% of variation for the presence of ACS. In
this model, elevated CRP concentration nearly doubled the
likelihood of ACS.
3.3. Diagnostic Accuracies of Investigated Markers. Finally, we
evaluated the ROC curves to assess diagnostic accuracies of
investigated variable for the prediction of ACS occurrence.
The highest level of discrimination of ACS was found for
CRP (area under the curve [AUC] = 0.80), however, this
was not significantly different from the diagnostic accuracy
of three other variables: TC : HDL-C (AUC = 0.78), LDL-
C : HDL-C, and TG : HDL-C (AUC = 0.77). The diagnostic
accuracies of all variables are shown in Figure 1.
For all measured parameters sensitivity, specificity, pos-
itive predictive value, and negative predictive value were
calculated. Among them, the most valuable results were
obtained for C-reactive protein and lipid ratios (Table 6). A
ROC analysis revealed an optimal cut-off point for CRP of
0.85 mg/L.
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Table 5: The risk of the acute coronary syndrome for primary and secondary variables.
Parameter
Crude odds ratio Adjusted odds ratio
Model 0∗ OR
P value for the model
Model 1 OR (95% CI)
P value for the model
Model 2 OR (95% CI)
P value for the model
Model 3 OR (95% CI)
P value for the model
TC
1.10 (0.95–1.29) 1.08 (0.96–1.22) 1.11 (0.98–1.26) 1.59 (0.66–3.83)
ns ns ns ns
LDL-C
0.90 (0.78–1.04) 0.87 (0.78–0.98) 0.85 (0.75–0.95) 0.59 (0.24–1.45)
ns 0.024 0.007 ns
HDL-C
0.88 (0.75–1.04) 0.95 (0.82–1.1) 0.92 (0.80–1.07) 0.42 (0.15–1.16)
ns ns ns ns
TG
0.99 (0.95–1.02) 1.01 (0.97–1.04) 0.99 (0.96–1.03) 0.80 (0.63–1.01)
ns ns ns ns
apoA-I
0.99 (0.96–1.02) 0.96 (0.92–1.01) 0.96 (0.92–1.01) 1.02 (0.87–1.2)
ns ns ns ns
apoB
0.99 (0.94–1.05) 0.99 (0.92–1.06) 0.99 (0.92–1.07) 0.97 (0.75–1.26)
ns ns ns ns
hsCRP 1.60 (1.31–1.95) 1.56 (1.21–2.01) 1.64 (1.26–2.13) 1.90 (1.34–2.89)
0.0001 0.001 0.0001 0.001
nonHDL-C 1.01 (0.97–1.04) 1.04 (0.99–1.09) 1.05 (0.99–1.1) 1.32 (0.85–2.04)
ns ns ns ns
TC : HDL-C
0.76 (0.8–6.81) 6.42 (0.32–125.6) 6.01 (0.25–145.3) 0.00 (0.27–104797)
ns ns ns ns
TG : HDL-C
0.92 (0.37–2.3) 0.36 (0.13–0.99) 0.38 (0.13–1.08) 976 (0.17–5713045)
ns 0.05 ns ns
LDL-C : HDL-C
2.75 (0.49–15.37) 0.92 (0.11–7.83) 0.72 (0.73–7.03) 12.1 (0.00–1.878E1)
ns ns ns ns
apoB : apoA-I
0.50 (0.001–402.2) 1.09 (0.01–10916) 0.39 (0.000–1853) 18.2 (0.000–4.117E1)
ns ns ns ns
∗Model 0 unadjusted: χ2 = 139.2; df = 12; P < 0.001; log-likelihood = 268.0; R2 Cox and Snell = 0.35; R2 Nagelkerke = 0.49.
Model 1 adjusted for age: χ2 = 251.8; df = 13; P = 0.001; log-likelihood = 155.4; R2 Cox and Snell = 0.54; R2 Nagelkerke = 0.75.
Model 2 adjusted for age and sex: χ2 = 259.6; df = 14; P < 0.001; log-likelihood = 147.6; R2 Cox and Snell = 0.55; R2 Nagelkerke = 0.77.
Model 3 adjusted for age, sex, and smoking status: χ2 = 233.4; df = 15; P < 0.001; log-likelihood = 50.9; R2 Cox and Snell = 0.64; R2 Nagelkerke = 0.90.
apoA-I: apolipoprotein A-I; apoB: apolipoprotein B; apoB : apoA-I: apolipoprotein B to apolipoprotein A-I ratio; CI: confidence interval; HDL-C: high-density
lipoprotein cholesterol; hsCRP: high-sensitivity C-reactive protein; LDL-C: low-density lipoprotein cholesterol; LDL-C : HDL-C: low-density lipoprotein
cholesterol to high-density lipoprotein cholesterol ratio; non-HDL-C: nonhigh-density lipoprotein cholesterol; ns: not significant; OR: odds ratio; TC: total
cholesterol; TC : HDL-C: total cholesterol to high-density lipoprotein cholesterol ratio; TG: triglycerides; TG : HDL-C: triglycerides to high-density lipoprotein
cholesterol ratio.
Table 6: Diagnostic usefulness of the assayed parameters for the occurrence of ACS.
Variable Cut-off value Sensitivity Specificity Positive predictive value Negative predictive value
CRP (mg/L)
0.85∗ 0.84 0.62 86% 58%
3.00# 0.48 0.89 90% 46%
TC : HDL-C 3.72 0.77 0.79 88% 63%
LDL-C : HDL-C 2.15 0.76 0.70 84% 59%
TG : HDL-C 1.55 0.85 0.59 81% 66%
apoB : apoA-I 0.53 0.74 0.56 77% 51%
∗
The optimal cut-off value for hsCRP test determined by ROC analysis in our study.
#A lower limit for the high risk category according the CDC and AHA statement on markers of inflammation and cardiovascular disease [6].
ACS: acute coronary syndrome; AHA: the American Heart Association; apoB : apoA-I: apolipoprotein B to apolipoprotein A-I ratio; CDC: the Centers for
Disease Control and Prevention; CRP: C-reactive protein; LDL-C : HDL-C: low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio;
TC : HDL-C: total cholesterol to high-density lipoprotein cholesterol ratio; TG : HDL-C: triglycerides to high-density lipoprotein cholesterol ratio.





























































Figure 1: The diagnostic value of measured and calculated
variables for the occurrence of acute coronary syndrome. apoA:
apolipoprotein A-I; apoB: apolipoprotein B; apoB : A: apolipopro-
tein B to apolipoprotein A-I ratio; CRP: C-reactive protein; HDL:
high-density lipoprotein cholesterol; LDL: low-density lipoprotein
cholesterol; LDL : HDL: low-density lipoprotein cholesterol to high-
density lipoprotein cholesterol ratio; nonHDL: non-high-density
lipoprotein cholesterol; TC: total cholesterol; TC : HDL: total
cholesterol to high-density lipoprotein cholesterol ratio, TG: tri-
glycerides; TG : HDL: triglycerides to high-density lipoprotein
cholesterol ratio.
4. Discussion
Our study clearly indicates that CRP possesses a higher prog-
nostic value in terms of ACS prediction than apolipoproteins
and lipid profile. ACS cases showed 4-fold higher median
CRP concentration on admission than healthy controls. The
difference in CRP level between patients with and without
ACS was much more pronounced in our data than for
apolipoproteins and lipid parameters and remained signifi-
cant after adjustment for age, sex, and smoking status. Fur-
thermore, assessment of the diagnostic accuracy confirmed
a very good ability of CRP to discriminate between cases
and controls. To increase the robustness of our findings
we enrolled into our study only patients diagnosed with
ACS within first 6 hours from the onset of chest pain.
We established this time frame restriction in the inclusion
criteria to minimize a potential impact of necrosis-related
inflammatory reaction on CRP concentration.
Elevated CRP concentration in patients who presented to
hospital with chest pain due to ACS was previously demon-
strated by others [19, 20]. In our study the highest CRP levels
were observed in NSTEMI and STEMI patients and were
considerably higher than in UA patients. These observations
are consistent with results of other researchers showing
higher CRP concentrations in patients with myocardial
infarction than with stable or unstable coronary artery dis-
ease [19–22]. Additionally, some investigators have reported
CRP levels to be higher in patients with STEMI than in
those with NSTEMI and noted their further and significant
decrease in patients with UA [21, 23]. However, in these trials
blood sampling beyond 6 hours from the onset of chest pain
was in agreement with the study protocols. Therefore, the
observed variation in CRP concentrations among the types
of ACS might be at least partially attributed to the differences
in the area of the infarcted myocardium. On the other
hand, there are also reports demonstrating lack of significant
differences in CRP concentrations at baseline among patients
with ACS [24, 25]. It should be also acknowledged that
elevated CRP concentration on admission is suggested to be
a marker for anatomic complexity of culprit lesions [23, 24].
CRP concentration above 3 mg/L, close to this present
in our ACS patients, is currently recommended by the
Centers for Disease Control and Prevention (CDC) and
the American Heart Association (AHA) as an independent
predictor of cardiovascular events in patients at intermediate
global risk (Class of recommendation IIa, Level of Evidence
B) [6]. Nevertheless, the optimal cut-off point for hsCRP
test determined by ROC analysis in our study was 0.85 mg/L.
This may indicate a higher diagnostic value of the test for
low concentrations of CRP. Our cut-off point is close to
1 mg/L, being a lower limit for the intermediate risk cate-
gory according the CDC and AHA statement. Calculations
performed using our data for the cut-off point of 3 mg/L
revealed a slightly lower sensitivity but higher specificity
than for the cut-off point of 0.85 mg/L. In line with our
findings, the results of the JUPITER trial support lower
than 3 mg/L cut-off point for increased cardiovascular risk.
In this randomized, placebo-controlled study of 17,802
apparently healthy persons with LDL-C concentration below
2.6 mmol/L but with hsCRP level of 2.0 mg/L or higher,
rosuvastatin significantly reduced the incidence of major
cardiovascular events [26]. Interestingly, another recent
study has addressed the prognostic efficacy of hsCRP in
ACS patients presenting within 6 hours from the onset of
chest pain and identification of the optimal cut-off value
to determine the long-term prognosis [27]. In this cohort
hsCRP level above 1.1 mg/L had the optimal positive and
negative predictive values.
Our study group, diagnosed with ACS, was diverse in
terms of established risk factors including dyslipidemia,
hypertension, diabetes, and smoking; each of them is capable
of explaining the occurrence of high CRP concentrations.
ACS patients have a higher risk of subsequent cardiovas-
cular events, featuring myocardial infarction, stroke, and
death. Primary and major strategies to diminish premature
cardiovascular morbidity and mortality should include the
identification and treatment of established risk factors,
especially hypertension, dyslipidemia, smoking, obesity, and
diabetes. Although the study group was characterized by
dyslipidemia, the median concentrations of lipids, except for
LDL-C and non-HDL-C, were within normal limits. Also,
the median concentration of apolipoprotein A-I and apoB
remained normal. The calculated atherogenicity indexes,
except for TC : HDL-C and LDL-C : HDL-C, also did not
exceed the reference values. However, although remaining
within normal ranges, there were statistically significant dif-
ferences concerning all parameters, compared with the
control group. It might be explained by the lower prevalence
of risk factors in the control group, since as evidenced by
the baseline characteristics, the prevalence of dyslipidemia,
hypertension, and smoking in this group was significantly
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lower and there were no patients with diabetes. The reduced
values of the lipid parameters could be also due to statin
therapy, which in the study group was received by 69% of
patients prior to admission. Despite ongoing statin therapy
the residual cardiovascular risk can still be significant in
patients with dyslipidemia [28]. In our study, significant
correlations between CRP and atherogenic indexes were
observed only among those diagnosed with ACS. As we
know, these indicators demonstrate the atherogenicity and
the presence of small dense LDL as well as insulin resistance
[29].
There is growing evidence that targeting other lipids,
such as triglycerides and HDL-C, is an important way
to reduce the residual cardiovascular risk, particularly in
patients with frank metabolic dysfunction [30]. In our study
we observed that out of the basic lipids and apolipoproteins
only HDL-C and apoA-I importantly limited the risk of
cardiovascular events, but not in every model, and that after
switching to models incorporating the secondary variables
such as atherogenicity indexes, this effect was negligible.
In contrast, we found that CRP significantly improved risk
prediction models’ accuracy and that it was the strongest
predictor of ACS in each of the logistic regression models
designed. ACS risk was highest for CRP compared with the
lipid parameters, atherogenicity indexes, and apolipopro-
teins (odds ratio = 1.9) in the model designed after adjust-
ment for age, sex, and smoking. To the best of our knowledge,
despite the large number of publications on CRP, to date
only few studies have been published concerning the clinical
utility of CRP in comparison with apolipoproteins and
simple lipid indexes calculated on the basis of the routine
lipid profile.
Based on a subanalysis of the PROVE IT-TIMI 22 trial
including ACS patients receiving statin therapy, Ray et al.
concluded that the addition of hsCRP to lipid-based
measurements significantly improved risk prediction, while
apoB : apoA-I, TC : HDL-C, non-HDL-C and LDL-C pro-
vided a similar risk prediction accuracy [31]. In con-
trast, the INTERHEART case-control study suggested that
apoB : apoA-I provides the highest odds ratio for myocardial
infarction occurrence compared with LDL-C and TC : HDL-
C, [32]. In the present study, CRP significantly improved risk
prediction irrespective of lipids, apolipoproteins, and their
calculated ratios included. Moreover, based on ROC curve
analysis, CRP becomes the most important discriminator
of ACS cases compared with other parameters. Besides the
role of CRP, considering the discrimination power assessed
by ROC analysis, also TC : HDL-C, LDL-C : HDL-C, and
TG : HDL-C showed similar and significant performance
for ACS prediction. The discrimination power was assessed
quantitatively as the AUC, which was 0.80 for CRP, 0.78 for
TC : HDL-C and 0.77 for LDL-C : HDL-C, and TG : HDL-
C. In contrast, other studies showed lower discriminative
usefulness of CRP. The AUCs for CRP in the NPHS-II trial
and in the EAS trial were 0.61 (95% confidence interval
0.57–0.66) and 0.62 (95% confidence interval 0.57–0.67),
respectively [33]. However, in these studies the measurement
of CRP at baseline was performed in healthy individuals
and perhaps due to this fact it provided only limited
discrimination for cardiovascular events compared with the
population burdened with additional risk factors.
In our study we failed to demonstrate any relation of
apoB and apoB: apoA-I with the onset of the cardiovascular
event. The lack of influence of apolipoproteins and the lipid
ratios on the occurrence of ACS could be explained by
the earlier use of statins in approximately 70% of patients;
however, it is not consistent with the fact that statins also
decrease CRP level independently of lowering LDL-C and
apoB concentrations [34]. This leads to the suggestion of the
pivotal role of inflammation in comparison to the subsidiary
involvement of small dense atherogenic lipoproteins in the
process leading to ACS.
Finally, it remains an unsolved issue whether CRP
directly contributes to atherothrombotic events and may be
a potential therapeutic target, or if it just reflects an increased
risk for unfavourable outcome as a bystander marker [8,
9]. A large body of basic scientific evidence suggests that
CRP possesses proatherogenic features. As demonstrated by
Williams et al., CRP increases the activity of matrix met-
alloproteinase 1 and collagenases produced by monocytes
and macrophages, which contributes to the destabilization
of atherosclerotic plaque [35]. CRP also displays throm-
bogenic activity via potentiation of thromboxane activity
[36]. Another study demonstrated a positive correlation
between the intensity of staining for the presence of CRP in
atherosclerotic lesions in coronary arteries, the concentration
of this protein in plasma, and the number of unstable plaques
with a thin fibrous cap [37]. Forte et al. showed that in
patients with ACS, CRP is produced and released within the
coronary circulation, which is associated with impairment of
endothelial function [38].
5. Limitations of the Study
Several limitations to our study should be acknowledged.
First, findings of our study due to its case-control design
associated with the potential for confounding may be rather
hypothesis-generating than definitive. Second, our cases and
controls slightly differed in terms of age and gender dis-
tribution. However, the strength of the association between
CRP concentration and the ACS occurrence in our study
was even greater after adjustment for these variables. Third,
we enrolled a broad spectrum of ACS patients and detailed
estimation of the relationship between CRP concentration
and the ACS occurrence may vary among different ACS
types. However, our inclusion criteria reflect a real-world
setting and at the early stage of ACS, when we collected
blood samples, it is usually unlikely to differentiate between
NSTEMI and UA. Fourth, we cannot exclude the modulatory
effect of prior statin therapy given in a substantial proportion
of cases on the obtained results. Fifth, we accounted in our
calculations neither for diurnal and seasonal variations in
CRP concentration nor for physical activity of the study par-
ticipants. Sixth, in our study we evaluated exclusively CRP,
apolipoproteins, and the traditional lipid profile. It remains
unclear whether novel biomarkers such as high-sensitivity
cardiac troponins, myeloperoxidase, growth differentiation
factor-15, and interleukin 1 receptor-like 1 (ST2) possess
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an additional predictive value to that obtained from CRP
measurement and validated risk scores [39, 40].
6. Conclusions
Our study indicates that CRP superiorly to apolipoproteins
and lipid profile facilitates the risk stratification for ACS
occurrence. However, large prospective cohort trials are
required to verify our findings and assess whether novel
biomarkers possess an additional predictive value to that
obtained from CRP measurement and validated risk scores.
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